How Should We Approach Cervical Cancer Screening in Japan?

— The Current Cytology-Based System and Japan’s Transitional Phase Toward HPV PCR Screening —

Introduction

Cervical cancer screening in Japan has long been conducted primarily using cytology (Pap smear).
While this approach has achieved a certain level of success, growing evidence in recent years has clearly established the causal relationship between HPV infection and the development of cervical cancer, prompting renewed discussion about the screening system itself.

This article aims to outline:

The characteristics of Japan’s cytology-based screening system
Its strengths and limitations
How Japan is currently beginning to transition toward HPV PCR–based screening

1️⃣ Japan’s Cytology-Based Cervical Cancer Screening System

Overview of the Current System in Japan

Primary screening test: Cytology (Pap smear)
HPV testing: Limited and supplementary
Screening interval: Every 1–2 years in most municipalities
Target population: Mainly women aged 20 years and older
Program structure: A decentralized system designed and implemented at the municipal level

2️⃣ Strengths of the Cytology-Based System

Japan’s cytology-centered screening program has several notable strengths:

A long history of use, with high familiarity and expertise among healthcare professionals
Direct evaluation of cytological abnormalities, allowing detection of existing cellular changes
Well-established nationwide infrastructure, including cytology laboratories and trained personnel

These factors have played an important role in supporting Japan’s screening system to date.

3️⃣ Limitations of the Cytology-Based Approach

At the same time, advances in medical evidence and changes in the social environment have highlighted several limitations.

Limited Sensitivity

Cytology detects outcomes (cellular changes) rather than the cause (HPV infection)
A proportion of CIN2+/CIN3+ lesions may be missed, resulting in false-negative results

Dependence on Frequent Screening

Due to sensitivity limitations, screening every 1–2 years is required
This places a significant burden on both patients and healthcare providers

Operator-Dependent Variability

Variability related to sample collection, slide preparation, and reader experience
Differences in quality between regions and institutions

Challenges in the HPV Vaccination Era

As HPV-vaccinated cohorts increase, cytological abnormalities become less frequent
Screening efficiency may decline

Difficulty Improving Participation Rates

Pelvic examination and clinician-collected samples are required
Psychological and time-related barriers remain

4️⃣ Emerging Movement Toward HPV PCR Screening in Japan

In recent years, Japan has also begun to move toward practical policy discussions and implementation of HPV PCR (HPV DNA testing) in cervical cancer screening.

This shift is driven by several factors:

Clear evidence that HPV infection is the primary cause of cervical cancer
Accumulation of domestic and international evidence supporting HPV testing
Increasing numbers of HPV-vaccinated cohorts
The need to balance screening accuracy with efficiency

Within expert panels and advisory committees convened by the Ministry of Health, Labour and Welfare, ongoing discussions include:

The appropriate role of HPV testing
Combined or stepwise transition models with cytology
Implementation strategies suited to Japan’s healthcare system

5️⃣ Japan’s Current Position: A Transitional Phase

Japan can be described as being in a transitional phase, seeking ways to incorporate HPV PCR screening while maintaining cytology as a foundation.

This transition does not represent a rejection of cytology, but rather reflects an evolution of the screening system in response to medical progress and changing societal conditions.

6️⃣ Key Considerations for Japan Moving Forward

Important issues for future discussion include:

How to integrate HPV PCR while preserving the strengths of cytology
Optimization of screening intervals and target age groups
Alignment with HPV vaccination policy
Reduction of disparities between municipalities

International recommendations, including those from the World Health Organization, may serve as useful references as Japan works to develop a realistic, stepwise screening model suited to its healthcare system and cultural context.

Conclusion

Japan’s cervical cancer screening program is now at a point where it must consider how to layer new screening technologies onto a well-established cytology-based foundation.

HPV PCR screening should not be viewed as a passing trend or simple alignment with overseas practices. Rather, it represents one practical option for improving screening accuracy, efficiency, and long-term sustainability, and is likely to become an increasingly realistic focus of policy discussion in the years ahead.

References

◆ World Health Organization